Last reviewed · How we verify
Taxotere-Cisplatin-5FU
Taxotere (docetaxel) works by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA, causing DNA damage and triggering cell death. 5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair.
Taxotere (docetaxel) works by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA, causing DNA damage and triggering cell death. 5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair. Used for Non-small cell lung cancer, Breast cancer, Stomach cancer.
At a glance
| Generic name | Taxotere-Cisplatin-5FU |
|---|---|
| Sponsor | Swiss Cancer Institute |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Taxotere's mechanism of action involves binding to tubulin, preventing microtubule formation and function, which is essential for cell division. Cisplatin forms platinum-DNA adducts, leading to DNA damage and triggering cell death through apoptosis. 5-FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis and repair, thereby disrupting these processes and inducing cell death.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Stomach cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- NESC: Neoadjuvant Treatment of Gastric Adenocarcinoma (PHASE2)
- tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
- Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer (PHASE3)
- Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |